BACKGROUND: The current situation in the treatment of chronic myeloid leukaemia (CML) presents a new challenge for attempts to measure the therapeutic results, as the CML patients can experience multiple leukaemia-free periods during the course of their treatment. Traditional measures of treatment efficacy such as leukaemia-free survival and cumulative incidence are unable to cope with multiple events in time, e.g. disease remissions or progressions, and as such are inappropriate for the efficacy assessment of the recent CML treatment. METHODS: Standard nonparametric statistical methods are used for estimating two principal characteristics of the current CML treatment: the probability of being alive and leukaemia-free in time after CML therapy initiation, denoted as the current cumulative incidence of leukaemia-free patients; and the probability that a patient is alive and in any leukaemia-free period in time after achieving the first leukaemia-free period on the CML treatment, denoted as the current leukaemia-free survival. The validity of the proposed methods is further documented in the data of the Czech CML patients consecutively recorded between July 2003 and July 2009 as well as in simulated data. RESULTS: The results have shown a difference between the estimates of the current cumulative incidence function and the common cumulative incidence of leukaemia-free patients, as well as between the estimates of the current leukaemia-free survival and the common leukaemia-free survival. Regarding the currently available follow-up period, both differences have reached the maximum (12.8% and 20.8%, respectively) at 3 years after the start of follow-up, i.e. after the CML therapy initiation in the former case and after the first achievement of the disease remission in the latter. CONCLUSIONS: Two quantities for the evaluation of the efficacy of current CML therapy that may be estimated with standard nonparametric methods have been proposed in this paper. Both quantities reliably illustrate a patient's disease status in time because they account for the proportion of patients in the second and subsequent disease remissions. Moreover, the model is also applicable in the future, regardless of what the progress in the CML treatment will be and how many treatment options will be available, respectively.

Institute of Biostatistics and Analyses Department of Mathematics and Statistics Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–1464. doi: 10.1056/NEJMra020777. PubMed DOI

Baccarani M, Saglio G, Goldman JM, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820. doi: 10.1182/blood-2006-02-005686. PubMed DOI

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. doi: 10.1056/NEJMoa022457. PubMed DOI

de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358–3363. doi: 10.1200/JCO.2007.15.8154. PubMed DOI

Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian H. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200–1206. doi: 10.1038/leu.2008.84. PubMed DOI

Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R) Cancer. 2009;115:4136–4147. doi: 10.1002/cncr.24504. PubMed DOI PMC

Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE, O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y, Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540–3546. doi: 10.1182/blood-2007-03-080689. PubMed DOI

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;58:457–481.

Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389–2430. doi: 10.1002/sim.2712. PubMed DOI

Craddock C, Szydlo R, Olavarria E, Dazzi F, Van Rhee F, Apperley J, Goldman J. Leukaemia free survival after allogeneic transplantation for chronic myeloid leukemia: effect of reclassifying responders to donor lymphocyte infusions as 'currently free of leukemia'. Blood. 1997;90(Suppl):327b.

Klein JP, Szydlo R, Craddock C, Goldman J. Estimation of current leukemia-free survival following donor lymphocyte infusion therapy for patients with leukemia who relapse after allografting: application of a multistate model. Stat Med. 2000;19:3005–3016. doi: 10.1002/1097-0258(20001115)19:21<3005::AID-SIM592>3.0.CO;2-9. PubMed DOI

Klein JP, Keiding N, Shu Y, Szydlo R, Goldman J. Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia-free survival curve. Br J Haematol. 2000;109:148–152. doi: 10.1046/j.1365-2141.2000.01982.x. PubMed DOI

Pepe MS. Inference for events with dependent risks in multiple endpoint studies. J Am Stat Assoc. 1991;86:770–778. doi: 10.2307/2290411. DOI

Al-Kali A, Kantarjian H, Shan J, Bassett R, Quintás-Cardama A, Borthakur G, Jabbour E, Verstovsek S, O'Brien S, Cortes J. Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer. 2011;117:327–335. doi: 10.1002/cncr.25604. PubMed DOI PMC

Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical Models Based on Counting Processes. New York: Springer; 1993.

Lin DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med. 1997;16:901–910. doi: 10.1002/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M. PubMed DOI

Efron B. Censored Data and the Bootstrap. J Am Stat Assoc. 1981;76:312–319. doi: 10.2307/2287832. DOI

Zackova D, Klamova H, Dusek L, Muzik J, Machova Polakova K, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J. Imatinib as the First Line Treatment of Patients with Chronic Myeloid Leukemia Diagnosed in the Chronic Phase: Can We Compare Real Life Data to the Results from Clinical Trials? Am J Hematol. in press . PubMed

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R. European LeukemiaNet. Chronic myeloid leukemia. An update of concepts and management recommendations of the EuropeanLeukemiaNet. J Clin Oncol. 2009;27:6041–6051. doi: 10.1200/JCO.2009.25.0779. PubMed DOI PMC

Datta S, Sundaram R. Nonparametric estimation of stage occupation probabilities in a multistage model with current status data. Biometrics. 2006;62:829–837. doi: 10.1111/j.1541-0420.2006.00529.x. PubMed DOI

Datta S, Satten GA. Validity of the Aalen-Johansen estimators of stage occupation probabilities and Nelson-Aalen estimators of integrated transition hazards for non-Markov models. Stat Probab Lett. 2001;55:403–411. doi: 10.1016/S0167-7152(01)00155-9. DOI

R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2010. http://www.r-project.org/

Klein JP, Shu Y. Multi-state models for bone marrow transplantation studies. Stat Methods Med Res. 2002;11:117–139. doi: 10.1191/0962280202sm277ra. PubMed DOI

Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, Kornblau S, O'Brien S, Cortes J. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113:6315–6321. doi: 10.1182/blood-2008-07-166694. PubMed DOI PMC

Meira-Machado L, de Uña-Álvarez J, Cadarso-Suárez C, Andersen PK. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res. 2009;18:195–222. PubMed PMC

Datta S, Satten GA. Estimation of Integrated Transition Hazards and Stage Occupation Probabilities for Non-Markov Systems Under Dependent Censoring. Biometrics. 2002;58:792–802. doi: 10.1111/j.0006-341X.2002.00792.x. PubMed DOI

Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol. 2010;21:2324–2332. doi: 10.1093/annonc/mdq204. PubMed DOI

Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2007;99:428–432. doi: 10.1093/jnci/djk091. PubMed DOI

Liu L, Logan B, Klein JP. Inference for current leukemia free survival. Lifetime Data Anal. 2008;14:432–446. doi: 10.1007/s10985-008-9093-1. PubMed DOI PMC